메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

Xinhua Silk Road: China's Tianjin, Jilin and Guangdong unveil joint proposal to deepen exchanges and cooperation in agriculture

BEIJING, Oct. 20, 2025 -- The 22nd China International Agricultural Trade Fair recently kicked off in northern China's Tianjin Municipality. During the event, Tianjin Municipality, Jilin Province and Guangdong Province jointly released the proposal on deepening exchanges and cooperation in agriculture. According to the proposal, the three regions will focus on key areas such as information sharing, standard setting, and market connectivity, with the aim of improving cooperation mechanisms and exploring new models for cross-regional development in agriculture. In the futu
- 황정호 기자
- 2025-10-20 16:14
AXA launches "WealthAhead II Savings Insurance" Series

[ 메디채널 황정호 기자 ] Empowering Customers to Accelerate Wealth and Plan for Succession EfficientlyMarket-first[1] Wealth Master Service [2]Customised Trust-like[3] Cash Flow Solutions for Up to Three Recipients HONG KONG, Oct. 20, 2025 -- AXA Hong Kong and Macau ("AXA") has launched the new WealthAhead II Savings Insurance Series[4] ("WealthAhead II Series" or the "Series"), an enhanced successor to the widely popular WealthAhead Savings Plan. WealthAhead II Series strengthens wealth management, wealth allocation, as well as wealth succession, supporting cus
- 황정호 기자
- 2025-10-20 15:14
Yamaha to Launch Subscription Version of "Mobile VOCALOID™ Editor"

[ 메디채널 김장윤(JASON KIM) 기자 ] Create Vocaloid songs anytime, anywhere. HAMAMATSU, Japan, Oct. 20, 2025 -- Yamaha Corporation will launch a subscription version of the "Mobile VOCALOID Editor an app for iPhone and iPad that allows users to create VOCALOID songs, on October 20 (Mon.) via the App Store. With this new subscription service, users can now enjoy an even easier way to experience VOCALOID music creation. Yamaha Software "Mobile VOCALOID Editor" (Subscription Version) URL: https://www.vocaloid.com/en/mveditor/ Developed by Yamaha in 2003, VOCA
- 김장윤(JASON KIM) 기자
- 2025-10-20 15:00
ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma

BERLIN, Oct. 20, 2025 -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by RemeGen Co., Ltd. was presented at the Presidential Symposium by Professor Jun Guo from Beijing Cancer Hospital. It's the first time a research led by Chinese scholars in the field of urological oncology has ever been selected in this honorable session. The full manuscript was simultaneously
- 김갑성 기자
- 2025-10-20 14:58
The Third Liangzhu Forum Opens in Hangzhou, Zhejiang

HANGZHOU, China, Oct. 20, 2025 -- On October 18, the Third Liangzhu Forum was held in Hangzhou, Zhejiang Province, jointly hosted by China's Ministry of Culture and Tourism, the National Cultural Heritage Administration, and the Zhejiang Provincial People's Government. The year 2025 marks the 40th anniversary of China's accession to the Convention Concerning the Protection of the World Cultural and Natural Heritage and the 20th anniversary of the adoption of UNESCO's Convention on the Protection and Promotion of the Diversity of Cultural Expressions. Themed "Revitalization
- 김장윤(JASON KIM) 기자
- 2025-10-20 14:24
"Connect to Innovation": UNISOC Uses Innovative Technology to Bring People Closer to the World

SHANGHAI, Oct. 20, 2025 -- As a technology company committed to "making connectivity accessible to everyone," UNISOC is working to bridge the global digital divide through innovation. In today's connected era, smartphones, wearables, and smart devices have become essential to how we live, work, and play. Yet, many people still cannot enjoy the convenience of high-quality connectivity. Research indicates that around 3.1 billion people remain offline, accounting for 38% of the global population — and 1.4 billion people aged 15 and above cannot afford a $30 smartphone. T
- 김장윤(JASON KIM) 기자
- 2025-10-20 14:23
Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power

BERLIN, Oct. 20, 2025 -- From October 17 to 21, the European Society for Medical Oncology (ESMO) Annual Congress convened in Berlin, bringing together global leaders in oncology and pharmaceutical innovation. Representing China's advancing biopharmaceutical landscape, Hengrui Pharma not only returned with a comprehensive portfolio of oncology research but also debuted as an exhibitor, marking a new milestone in its global academic engagement. Since 2016, Hengrui has presented pioneering research at the ESMO Annual Congress for ten consecutive years. This year, the company unveiled 46 s
- 김갑성 기자
- 2025-10-20 14:20
From Corporate Social Responsibility To Global Consensus: Chery's "Ride Green Life" Unites the World for a Sustainable Future

WUHU, China, Oct. 20, 2025 -- As the global automotive industry accelerates toward a green, low-carbon future, corporate social responsibility has evolved — now defined by sustainable practices fostering harmony between people, society, and nature. As a globally recognized automotive brand, Chery continues to drive this vision through long-term, tangible actions uniting technology, humanity, and nature in balance. On October 20, the third "Ride Green Life" Charity cycling event officially took place along the Yangtze River in Wuhu. As a key event of the 2025 Chery Internation
- 황정호 기자
- 2025-10-20 14:04
Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions

LONDON, Oct. 20, 2025 -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries. This strategic move enhances Accord B.V.'s commitment to improving global access to plasma-derived medicines and strengthens its ability to meet the increasing demand for life-saving plasma therapies worldwide. Prothya Biosolutions is one of Europe's leading plasma fractionators, operating major facilities in Amsterdam and Brussels, along with plasma collection centr
- 김갑성 기자
- 2025-10-20 14:00
어코드 플라스마, 프로시아 바이오솔루션스 인수로 글로벌 혈장 치료 역량 강화

런던, 2025년 10월 20일 -- 인타스 파마슈티컬스(Intas Pharmaceuticals)의 자회사인 어코드 플라스마(Accord Plasma B.V.)가 20일 프로시아 바이오솔루션스 벨기에(Prothya Biosolutions Belgium BV) 및 그 자회사들의 인수를 성공적으로 완료했다고 밝혔다. 이번 전략적 조치를 통해 어코드는 혈장분획제제(plasma-derived medicinal products•PDMPs)에 대한 글로벌 접근성을 개선한다는 자사의 의지를 한층 더 강화하고, 전 세계적으로 증가하는 생명 구호 혈장 치료제 수요를 충족시킬 수 있는 능력을 높이게 됐다. 프로시아 바이오솔루션스는 유럽을 선도하는 혈장분획업체 중 하나로, 암스테르담과 브뤼셀에 주요 시설을 운영하며, 헝가리 전역에 혈장 수집 센터를 보유하고 있다. 회사는 약 1200명의 숙련된 전문가를 고용하고 있다. 전 세계적 혈장 치료 접근성 확대 프로시아와의 통합으로 어코드는 혈장 역량이 크게 향상됐다. 유럽에서 입증된 프로시아의 전문성과 인타스가 인도에서 확보한 대규모 분획 인프라를 결합함으로써 다양한 지
- 김갑성 기자
- 2025-10-20 14:00

이전

51 52 53 54 55 56 57 58 59 60

많이 본 기사

최근기사

2025-11-01_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 01일 15시 40분